New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma in Germany: TIGER Study

Novocure has unveiled new data from the TIGER study, which investigates Tumor Treating Fields (TTFields) therapy in the treatment of newly diagnosed glioblastoma (GBM) patients in Germany. This study, which is the largest prospective, non-interventional study of its kind to date, enrolled 429 patients from August 2017 to November 2019. These patients were monitored for a median duration of 56.2 months.

The primary findings show that the median overall survival for patients using TTFields therapy was 19.6 months, while the median progression-free survival was 10.2 months. The one-year survival rate for these patients stood at 79.2%. Two-year, three-year, and four-year survival rates were recorded at 42.4%, 31.5%, and 27.7%, respectively. The therapy was reported to be well tolerated without increasing systemic toxicity. These results align with those observed in Novocure's previous phase 3 EF-14 clinical trial.

Dr. Oliver Bähr from the Department of Neurology at General Hospital Aschaffenburg-Alzenau remarked on the significance of the findings, emphasizing that the outcomes, particularly the long-term survival rates, underline the potential benefits of TTFields therapy for eligible GBM patients. Similarly, Dr. Nicolas Leupin, Novocure's Chief Medical Officer, highlighted that the study further confirms the efficacy and safety of TTFields therapy, strengthening its case as a viable treatment option in both clinical and real-world settings.

The TIGER study, officially known as NCT03258021, aimed to gather real-life data on the use of TTFields therapy in routine clinical care for GBM patients across Germany. It involved patients who had been newly diagnosed with GBM and were within the first three cycles of maintenance chemotherapy. Of the 710 patients enrolled, 583 chose to use TTFields therapy, and ultimately, 429 received the treatment. The study's endpoints focused on overall survival, progression-free survival, safety, and quality of life.

TTFields therapy operates by using electric fields to target and kill cancer cells through various mechanisms while sparing healthy cells due to their differing properties. This multimechanistic approach allows TTFields to be combined with other cancer treatment modalities, such as chemotherapy and radiotherapy, enhancing its effects across a range of solid tumors.

Novocure, the company behind TTFields therapy, is dedicated to extending survival in aggressive cancers through innovative therapies. Headquartered in Root, Switzerland, Novocure has a global presence with operating centers in Portsmouth and Tokyo, and a research center in Haifa, Israel. The company continues to explore the benefits of TTFields therapy in various types of solid tumors through ongoing and completed clinical studies.